Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Spyre Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
SYRE
Nasdaq
2836
www.spyre.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Spyre Therapeutics, Inc.
Spyre Therapeutics to Participate in Upcoming Investor Conferences
- Nov 10th, 2026 6:00 am
Spyre Therapeutics (SYRE) Stock Trades At A Premium To Book Value
- Nov 7th, 2026 2:10 pm
Spyre Therapeutics Announces Grants of Inducement Awards
- Nov 6th, 2026 2:05 pm
Spyre Therapeutics: Q3 Earnings Snapshot
- Nov 3rd, 2026 2:12 pm
Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Nov 3rd, 2026 2:01 pm
Spyre Therapeutics (SYRE) Stock May Be Fully Priced Following New IBD Data Preview
- Oct 23rd, 2026 7:15 pm
Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says
- Oct 20th, 2026 10:48 am
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
- Oct 18th, 2026 7:30 am
Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering
- Oct 8th, 2026 11:15 am
Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
- Oct 6th, 2026 11:40 am
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
- Oct 5th, 2026 6:13 pm
Spyre Therapeutics stock falls on public offering launch
- Oct 5th, 2026 2:46 pm
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
- Oct 5th, 2026 2:01 pm
Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls
- Oct 1st, 2026 7:38 am
What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis?
- Sep 22nd, 2026 10:16 am
Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight
- Sep 21st, 2026 11:00 am
Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests
- Sep 17th, 2026 1:04 am
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?
- Sep 10th, 2026 5:59 pm
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
- Sep 9th, 2026 7:56 am
Scroll